{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T03:34:30Z","timestamp":1758944070868,"version":"3.37.3"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.leukres.2019.106231","type":"journal-article","created":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T13:34:40Z","timestamp":1569677680000},"page":"106231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Chronic myeloid leukaemia: The dangers of not knowing your BCR-ABL1 transcript"],"prefix":"10.1016","volume":"87","author":[{"given":"Kirsty","family":"Sharplin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haley","family":"Altamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Wellwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Branford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.leukres.2019.106231_bib0005","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1634\/theoncologist.2015-0337","article-title":"Best practices in chronic myeloid leukemia monitoring and management","volume":"21","author":"Soverini","year":"2016","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.leukres.2019.106231_bib0010","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2019.106231_bib0015","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"year":"2019","series-title":"NCCN Chronic Leukaemia V One 2019: Clinical Practice Guidelines in Oncology","key":"10.1016\/j.leukres.2019.106231_bib0020"},{"key":"10.1016\/j.leukres.2019.106231_bib0025","first-page":"69","article-title":"Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR","volume":"125","author":"Branford","year":"2006","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.leukres.2019.106231_bib0030","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1038\/bcj.2017.62","article-title":"Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia","volume":"7","author":"Gong","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2019.106231_bib0035","first-page":"122","article-title":"Chronic myeloid leukemia (CML) patients with atypical e1a2 P190 BCR-ABL translocation show a poor response to therapy with tyrosine kinase inhibitors (TKI)","author":"Montoriol-Sabat\u00e9","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2019.106231_bib0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1517\/17530050903483187","article-title":"Molecular diagnostics in chronic myeloid leukemia","volume":"4","author":"Lange","year":"2010","journal-title":"Expert Opin. Med. Diagn."},{"issue":"114","key":"10.1016\/j.leukres.2019.106231_bib0045","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1182\/blood-2009-02-204693","article-title":"Chronic myeloid leukemia (CML) with P190 BCR-ABL\u202f:analysis of characteristics, outcomes, and prognostic significance","author":"Verma","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2019.106231_bib0050","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/blood.V128.22.1918.1918","article-title":"Assessment of molecular response in CML patients with atypical BCR-ABL transcripts: recommendations by the EUTOS collaboration","author":"Ernst","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2019.106231_bib0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2353\/jmoldx.2009.080095","article-title":"Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology","volume":"11","author":"Jones","year":"2009","journal-title":"J. Mol. Diagn."},{"issue":"10","key":"10.1016\/j.leukres.2019.106231_bib0060","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.mayocp.2015.08.010","article-title":"Diagnosis and treatment of chronic myeloid leukemia in 2015","volume":"90","author":"Thompson","year":"2015","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"10.1016\/j.leukres.2019.106231_bib0065","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2019.106231_bib0070","first-page":"5619","article-title":"How to detect the rare BCR-ABL (e14a3) transcript: a case report and literature review","volume":"14","author":"Hu","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.leukres.2019.106231_bib0075","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2002-03-0930","article-title":"CML with an e1a3 BCR-ABL fusion: rare, benign, and a potential diagnostic pitfall","volume":"100","author":"Al-Ali","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2019.106231_bib0080","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/2040620716657994","article-title":"Current developments in molecular monitoring in chronic myeloid leukemia","volume":"7","author":"Marum","year":"2016","journal-title":"Ther. Adv. Hematol."},{"issue":"5","key":"10.1016\/j.leukres.2019.106231_bib0085","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3324\/haematol.2010.034389","article-title":"Cartridge-based automated BCR-ABL1 mRNA quantification: solving the issues of standardization, at what cost?","volume":"96","author":"Cayuela","year":"2011","journal-title":"Haematologica"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619301766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619301766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T19:28:24Z","timestamp":1575314904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212619301766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":17,"alternative-id":["S0145212619301766"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2019.106231","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic myeloid leukaemia: The dangers of not knowing your BCR-ABL1 transcript","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2019.106231","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2019 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106231"}}